Europe continues to battle counterfeiters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe continues to battle counterfeiters
Governments, regulators and international agencies continue to defend against counterfeiters; in particular, the European Commission has outlined measures that may help to better regulate pharmaceutical distributors. There is still much work to be done, however, particularly when it comes to counterfeit drugs sold via the internet.


Pharmaceutical Technology Europe
Volume 21, Issue 12

References

1. IMS Health, IMS Health Market Prognosis (2009). http://www.imshealth.com/

2. European Federation of Pharmaceutical Industries and Associations, "Combating counterfeit medicines and protecting patients through a partnership approach" (2005). http://www.efpia.eu/

3. Europa, "Protecting the legal supply chain against counterfeited medicines" (2008). http://europa.eu/

4. International Narcotics Control Board, "INCB warns of counterfeit medicines flooding markets" (2007). http://www.incb.org/

5. Europe Economics, "Policies to Combat Counterfeit Medicines: Contribution to Impact Assessment" (2008). http://www.europe-economics.com/

6. Partnership for Safe Medicines, "Counterfeit Drugs in Europe" (2005). http://www.safemedicines.org/

7. European Federation of Pharmaceutical Industries and Associations, "Zero tolerance for counterfeit medicines" (2009). http://www.efpia.eu/

8. European Commission, "Summary of responses to the public consultation document on a legislative proposal to combat counterfeit medicines for human use" (2008). http://ec.europa.eu/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here